Genentech and Biogen Idec say that the Phase II data for Rituxan as a therapy for multiple sclerosis exceeded their expectations. "Showing a significant benefit at 24 weeks in this small Phase II trial supports our hypothesis that selective B-cell targeted therapy may play an important role in the treatment of MS," said Genentech senior VP Hal Barron MD. Report